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Project summary 
Project: 
Author: 
Development of a revised Drug Harm Index 
Dr Michael McFadden, Director McFadden Consultancy 
Aim The new Drug Harm Index provides a comprehensive evaluation of the costs of 
harmful illicit drug use, focusing on the social cost of use by drug type. Estimates of 
total harm, harm per kilogram of drug consumed and harm per user are included. 
Illicit drugs include legal drugs diverted to the illicit drug market and exclude alcohol 
and tobacco. 
Method The method involved identifying the number of drug users and the extent of drug use 
by category of drug. Where hard data existed (e.g. drug-related deaths, treatment 
sessions, crime statistics), the estimated harm was calculated for given drug types. In 
the absence of hard data, expert opinion (following a method developed by Nutt et al, 
2010) was used to provide a basis for the future estimate of the dollar harms for 
drugs. Unlike previous drug harm indexes, the social cost of harm associated with 
drug use (personal harm and community harm) was separated from the costs 
associated with attempts to address the issue (intervention costs). Cost estimates 
included explicitly for the first time include harm to family and friends of drug users, 
funding of other criminal activities and reduction in taxation revenue. 
Results The estimated social cost of drug-related harms and intervention costs in 2014/15 
was $1.8 billion. Details are given below. 
Drug group Personal 
harm $(m) 
Community 
harm $(m) 
Total harm 
$(m) 
Intervention 
cost $(m) 
Total social 
cost $(m) 
Amphetamine-
type stimulants 
256.4 91.4 347.8 16.4 364.2 
Cannabinoids 256.4 720.3 976.7 305.9 1,282.6 
Hallucinogenic 
and psychedelic 
drugs 
8.0 9.0 17.0 5.3 22.3 
Opioid and 
sedative drugs 
80.1 72.0 152.1 23.8 175.9 
Total 601.0 892.7 1,493.7 351.4 1,845.0 
 
 
Discussion The new Drug Harm Index is a conservative measure of the harms associated with the 
use of illicit drugs in New Zealand. The Index can be extended to accommodate new 
and emerging drugs into the Index in the future. This method will also extend the 
useful life of the proposed Drug Harm Index. It provides new insights into who 
actually suffers from the burden imposed by illicit drug use. 
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Introduction 
The first published Drug Harm Index (DHI) was developed by the Australian Federal Police during 
2001 in response to the Australian Government’s interest in the social impact of its policies to curb 
the abuse of illicit drugs (McFadden et al, 2002) and subsequently revised in 2003, 2006 and 2008 
(Attewell & McFadden, 2008). It was followed by other DHIs, including Great Britain in 2005, the 
United Nations Office on Drugs and Crime (UNODC) in 2005 and New Zealand in 2008 (MacDonald 
et al, 2006; UNODC, 2005; Slack et al, 2008). 
As in Australia, the main impetus for the development of a DHI elsewhere was an interest in 
measuring the impact of government policy in relation to illicit drugs. The success or otherwise of a 
DHI in accomplishing this goal is heavily dependent on the ability to specify in detail what is expected 
from its application. In New Zealand this important step was completed in 2008, and in the current 
project it is subject to further revision. The following section provides more detail on what is 
expected of a DHI in the New Zealand context. 
Research scope 
The scope of the task was defined in the Request for Proposal issued by the Ministry of Health on 
29 May 2015. An excerpt is provided here to clarify the purpose of the project. 
The Ministry of Health is seeking Proposals from organisations with the skills and expertise 
necessary to develop an updated Drug Harm Index that builds on previous work in 2008. The new 
Drug Harm Index will provide a comprehensive evaluation of the costs of harmful illicit drug use, 
focusing on the social cost of use per drug type. This is subject to the agreement of parameters 
and methodology for developing a new updated Drug Harm Index. As well as the drug types 
considered in the previous Index, this Index will consider NBOMEs and other unapproved 
psychoactive substances, reflecting the ever changing drug scene in New Zealand. As part of this 
work, we require Respondents to: 
• Develop and agree a methodology for a new Drug Harm Index 
• Develop a new Drug Harm Index 
• Provide other relevant advice, including how the Drug Harm Index can be maintained. 
Development of a new Drug Harm Index and the associated report should assist agencies assess 
the costs and benefits of their current interventions; assist agencies evaluate how effective they 
have been in achieving the aims of the National Alcohol and Other Drug Policy; alert policy 
makers to the cost of harms associated with new drugs that have been introduced or are 
becoming more prevalent; help guide future enforcement activities and harm reduction 
strategies; and to inform future advice about how best to manage a reduction in harm caused by 
illicit drugs.1 
The project is a collaborative one, with the active involvement of a number of government and non-
government agencies. The project relies on work that has gone before, including research by Slack 
and others on behalf of the New Zealand Police (Slack et al, 2008), the original research by the 
Australian Federal Police (Attewell & McFadden, 2008), Moore’s estimates of harms per kilogram of 
 
1 Request for Proposal, Development of a New Drug Harm Index. Date RFP issued: Friday, 29 May 2015. 
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drug consumed (Moore, 2007), and the expert panel survey of drug harms (Nutt et al, 2010). The 
current study was constructed on the foundations laid by these earlier works. 
There are core components of the DHI that have remained the same through the various versions: 
• the identification of drugs of interest − these include all illicit drugs and legal drugs diverted 
to the illicit market (alcohol and tobacco are excluded) 
• an estimate of the total harm to the community caused by illicit drugs, expressed in dollar 
terms (all dollars are New Zealand dollars unless otherwise stated) 
• a method for distributing these costs against drugs of interest 
• an estimate of consumption for each drug of interest 
• calculation of total dollar harm for each drug of interest 
• the calculation of an average dollar harm per kilogram of specific drug consumed. 
In addition, the original New Zealand DHI has an estimate of dollar harm per drug user. 
The first task of the current project was to update existing estimates. The second task was to 
calculate estimates of harm for new and emerging drugs. The latter is a major issue for maintaining 
the relevance of the DHI. The issue is not dissimilar from the problem of dealing with existing drugs 
whose harms are not well known, and the solution, as indicated later, is the same. 
Report structure 
There are differences in the content and method employed in this version compared with the original 
version of the New Zealand DHI. The current report adopts a different methodology, introduces 
some innovative techniques and varies from the approach adopted in the earlier report, where this 
was deemed appropriate. The emphasis was on building on the earlier report rather than replacing it 
or copying its approach. Nevertheless, in order to assist the reader in cross-referencing the two 
studies, this report has been structured as far as possible to reflect the structure of the earlier DHI 
report (Slack et al, 2008). 
Following this introduction, the report reviews existing knowledge and its implications for the 
project, before outlining the method in detail. This is followed by an overview of drug use in New 
Zealand. Next comes a section on drug harm calculation, which is the backbone of the report and has 
a matching degree of detail. The results and recommendations sections describe the output of the 
calculation and their implications. Separate sections are devoted to the practical application of the 
new DHI and a consideration of potential future directions for the maintenance and application of 
the DHI. 
There are two technical attachments to the report. These are included for individuals with both the 
interest and skills to follow the logic of the processes involved in compiling the New Zealand DHI 
2016. Attachment A provides details of the methods used to estimate the extent of drug 
consumption, and Attachment B has a similar level of detail in relation to the calculation of harm. 
These calculations are necessarily complex, and further information or explanation can be obtained 
by contacting the author. 
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The report also includes a number of observations arising from the development of the DHI. These 
are items of interest related to the purpose of the paper but not essential to understanding its main 
theme. The reader may safely ignore these inserts, which are clearly labelled. For some, these will 
provide greater insight into the workings and implications of the new DHI. 
It should be noted that the development of a DHI involves the specification of a complex model with 
numerous assumptions. It is preferable that all such assumptions be made explicit, but in practice 
this is not always the case. Typically, researchers will describe the assumptions underlying their 
model; they are less likely to describe the assumptions underlying estimates imported from other 
sources. 
Due to their complexity models are not really ‘right’ or ‘wrong’. Rather their validity is assessed by 
how well they fit the world they are attempting to describe. The critical aspect of any model is to be 
sufficiently transparent to permit an independent evaluation of its worth. In keeping with this 
approach, the current report was subject to independent professional review. 
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Background 
This section provides a brief history of DHIs developed in New Zealand and elsewhere. The following 
summary is based largely on that produced by Attewell and McFadden (2008). In fact, 2008 marks a 
watershed year in relation to the development of DHIs. Six separate DHIs were developed in the 
years 2001−2008 and none since. The summary is followed by a literature review of relevant, though 
sparse, post-2008 publications. 
A brief history 
As indicated earlier, the first published DHI was developed for the Australian Federal Police in 2001. 
At that time the development of an index was in response to two quite separate issues. 
• Law enforcement had long struggled with the reporting and interpretation of illicit drug 
seizures. There were, and still are, two options for most agencies. Reporting the number 
and weight of seizures by drug type provides an accurate picture of what has occurred, but 
it is difficult to interpret in terms of general trends. A decrease in seizures of one drug type 
might be counterbalanced by an increase for another drug type. The alternative is simply to 
report the aggregate number and weight for all seizures across all drug types. This has the 
benefit of being a single number, but it is remarkably coarse. 
• The Australian Government had introduced an output−outcome reporting regime for 
Commonwealth departments to increase departmental accountability and shift agencies’ 
perspective from an emphasis on properly acquitting the funds provided to an emphasis on 
the social impacts of government programmes. 
Nearly all public sector agencies struggle with measuring the social impact of their programmes. This 
is hardly surprising given that government programmes operate in complex environments, with 
many other players, forces and environmental factors involved. The original DHI provided law 
enforcement with a way of reporting its drug seizure activity in a single meaningful number that also 
represented the dollar value of its social impact to the community. In 2007 the Victorian Police began 
developing a DHI, and one year later the New Zealand Police introduced its own version (Willis et al, 
2010; Slack et al, 2008). 
Although the DHI was originally developed in a law enforcement context, its wider applicability was 
soon recognised in that a single index would be of value in tracking the total harm caused by illicit 
drugs. This approach involves a weighted aggregate of key harm measures such as mortality, 
morbidity and drug-related crime. It was this latter application that led to the development of the 
Home Office Drug Harm Index in the United Kingdom in 2004 (MacDonald et al, 2006). A similar 
approach was adopted by the UNODC in developing its Illicit Drug Index in 2005 to provide a single 
measure of harm across regions and countries, and across time (UNODC, 2005, 2006). An excerpt 
from Attewell and McFadden (2008) provides a summary of the similarities and differences between 
the various measures: 
All are used as summary measurements to compare policy outcomes either internally or 
externally. However, there are differences in approach and method. The United Kingdom index 
concentrates on a set of measurable indicators that are related to the social harms caused by 
drugs. The index for the base year (1988) was set at 100, and subsequent levels of harm were 
plotted against that point. Thus, it is a relative rather than an absolute measure of harm. The AFP 
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and New Zealand indices share the same methodology, the only difference being that AFP had an 
independent estimate of the economic cost of drug use in the community, whereas the New 
Zealand study developed its own measurements. Both forms of measurement provide absolute 
estimates of the level of harm in economic terms, and both are used by their respective law 
enforcement agencies to report performance. There are differences: the bottom-up approach 
used in New Zealand resolved the issue of double-counting harm by counting polydrug users in 
each of the relevant drug categories. The top-down approach used in Australia avoided this 
problem by segmenting harm at the aggregate level. The issue remains important if harm at the 
drug-user level is of interest. (p. 42) 
Of the various DHIs developed between 2001 and 2008, only two remain in use, the New Zealand DHI 
and the Australian DHI. I have been unable to locate any public explanation of the fate of the UK and 
UNODC DHIs. Personal communication with the Home Office and the UNODC remains unanswered 
after several months and repeated requests. From the published material it appears that neither DHI 
was in use three years after its inception. 
It should be noted that the Victorian Police version was always an internal measure and not subject 
to public scrutiny. The reasons for the survival of the two law enforcement-sponsored DHIs is not 
altogether clear. Possibly the ability of the respective DHIs to provide feedback in an organisational 
environment that is conducive to feedback may be one factor. It should also be noted that these 
DHIs report results in dollar values, which assists interpretation by the general public and 
professional community alike. In short, they have a clear message. 
Literature review post-2008 
The literature review post-2008 was conducted using Google, Google Scholar and university library 
research engines using the key words ‘drug harm index’. The following reports were identified as 
potentially relevant: 
Greenfied V & Paoli L (2010). If supply-oriented drug policy is broken, can harm reduction help fix it? 
Melding disciplines and methods to advance international drug control policy, United States 
Naval Academy, Department of Economics, Working Paper 2010–30. 
Melberg H, Hakkarainen P, Houborg E, Jääskeläinen M, Skretting A, Ramstedt M & Rosenqvist P 
(2011). Measuring the harm of illicit drug use on friends and family, Nordic Studies on Alcohol 
and Drugs, 28, 2, 105–121. 
Morgan C, Muetzelfeldt L, Muetzelfeldt M, Nutt D & Curran H (2010). Harms associated with 
psychoactive substances: findings of the UK National Drug Survey, Journal of 
Psychopharmacology, 24, 2, 147–153. 
Nutt D, King L and Phillips L (2010). Development of a rational scale to assess the harm of drugs of 
potential misuse, The Lancet, 369, 9566, 1047–1053. 
Pedersen W & Von Soest T (2015). Which substance is most dangerous? Perceived harm ratings 
among students in urban and rural Norway, Scandinavian Journal of Public Health, 43, 
385–392. 
Reuter P (2009). Ten years after the United Nations General Assembly Special Session (UNGASS): 
assessing drug problems, policies and reform proposals, Addiction, 104: 510–517. 
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Ritter A (2009), Methods for comparing drug policies – the utility of composite Drug Harm Indexes, 
International Journal of Drug Policy, 20, 6, 475–479. 
van Amsterdam J, Opperhuizen A, Koeter M & van den Brink W (2010). Ranking the harm of alcohol, 
tobacco and illicit drugs for the individual and the population, European Addiction Research, 
16, 4, 202–207. 
There are two strands in the literature post-2008. The first relates to critiques of existing DHIs. In 
general, most commentators were sympathetic to the aims of developing a DHI (Greenfield & Paoli, 
2010; Nutt el al, 2010; Ritter, 2009). In this they were consistent with a 2006 review conducted by 
the Beckley Foundation (Roberts et al, 2006). The notion of a single measure of drug harm that can 
be used to measure the benefits of illicit drug policy and practice is highly appealing. Most realised 
the problems that beset the measurement of any behaviour that is illegal. Reuter (2009) was more 
sceptical, suggesting that any single measure of drug-associated harms was unlikely to capture the 
complexity of the environment within which drug markets operate. 
The second strand relates to an innovative approach to measuring harm. Nutt et al (2010) proposed 
the use of expert opinion to develop a scale of drug harm. They noted that drug abuse is a major 
health issue and that drugs are regulated by a classificatory system in the UK that purportedly 
reflects their relative harm, but that the basis for the classification is not transparent. They 
developed a classification system based on rankings provided by experts in the field. The ranking 
covered both legal and illegal drugs. 
Despite the fact that their interest was in creating a rational and defensible classificatory system for 
illicit drugs, it was immediately apparent that this approach had application to the development of 
DHIs. In fact, the 2008 revision of the Australian DHI incorporated this approach into its methodology 
by transferring the UK rankings to the Australian context (Attewell & McFadden, 2008) using an 
earlier version of the paper reported in The Lancet (Nutt el al, 2010). The work by Nutt et al was also 
impressive because it provided the results in a way that could be readily understood and conveyed. 
See Insert 1 on the following page, an excerpt from The Economist of 2 November 2010 (The 
Economist, 2010). 
This seminal work provided the impetus for a number of papers relating to perceived level of harm, 
as estimated by users or the general public rather than by expert groups (Melberg et al, 2011; 
Morgan et al, 2010; Pedersen & Von Soest, 2015; van Amsterdam et al, 2010). Morgan et al 
conducted a survey of 1,501 drug users in the UK and found a high correlation between the rankings 
provided by users and those provided by the experts of the Nutt et al (2010) study. In general, there 
is considerable consensus between experts, users and independent assessments (such as the various 
DHIs) on the relative harm associated with traditional drug types, which provides a strong 
underpinning for further work in the area. The question is not about which drugs cause harm but 
rather how we can quantify in economic terms our existing consensus on the relative harm created 
by illicit drugs. 
In an important extension of the survey technique to measure harm, Melberg et al (2011) included a 
willingness-to-pay question into a survey of drug harm. Willingness-to-pay, as the phrase implies, is a 
technique to measure how much a community is willing to pay to achieve a given outcome. Melberg 
et al found that one in fourteen members of the public knew socially or were related to a drug user 
(i.e. family and friends). Family and friends of drug users indicated they would be willing to spend 
between 500 and 13,000 euros to treat the drug user. 
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The other highly relevant aspect of the Melberg et al study is that it draws attention to a type of 
harm not included in previous DHIs, namely the harm to family and friends. The inclusion of this 
harm was an innovative feature of the current study. The Melberg et al study and its implications will 
be discussed in greater detail later. 
INSERT 1. 
Nov 2nd 2010, 12:30 by The Economist online 
A new study suggests alcohol is more harmful than heroin or crack 
Most people would agree that some drugs are worse than others: heroin is probably 
considered to be more dangerous than marijuana, for instance. Because governments 
formulate criminal and social policies based upon classifications of harm, a new study 
published by the Lancet on November 1st makes interesting reading. Researchers led by 
Professor David Nutt, a former chief drugs adviser to the British government, asked drug-harm 
experts to rank 20 drugs (legal and illegal) on 16 measures of harm to the user and to wider 
society, such as damage to health, drug dependency, economic costs and crime. Alcohol is the 
most harmful drug in Britain, scoring 72 out of a possible 100, far more damaging than heroin 
(55) or crack cocaine (54). It is the most harmful to others by a wide margin, and is ranked 
fourth behind heroin, crack, and methamphetamine (crystal meth) for harm to the individual. 
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Implications for study 
Several issues arose from the literature review. The first is the importance of knowing the question 
one is attempting to answer. There are two broad streams in the experience with DHIs to date. Some 
parties (including the UK and the UNODC) are primarily interested in mapping the total harm 
attributable to illicit drug use across both time and place. Other parties, primarily law enforcement, 
are more interested in assessing the value of their intervention to curbing the social harms 
associated with the use of illegal drugs. In terms of what is counted in the measurement of harm, 
one aim (impact of intervention) is a subset of the other (total harm attributable to drugs). 
For our purposes, the total cost of illicit drug use can be considered to have three components: 
A. the cost of personal harm (i.e. the harms that descend upon an individual as a consequence 
of their drug use), which will comprise physical health, psychological wellbeing and 
personal wealth 
B. the cost of community harm (i.e. the cost of crime attributable to drug use, injury to others, 
the various harms to family and friends and a reduced tax base) 
C. the cost of intervention − interventions occur as a result of attempts to address the harms 
associated with illicit drug use and include health, education and law enforcement. 
The total harm attributable to illicit drug use is the sum of two components: 
Total Harm Cost = A + B 
As noted, interventions are an attempt to address the harm associated with illicit drugs, not a harm 
per se. Nevertheless, the community incurs a social cost in providing funds for these interventions, 
and the opportunity to devote these funds to other worthwhile purposes is lost. Thus, the total social 
cost of illicit drugs can be described as: 
Total Social Cost = A + B + C 
Within this report, total harm is seen as being different from social cost. This breaks a long tradition 
of including ‘intervention costs’ as harms. This interpretation is certainly novel and may appear 
counterintuitive. Consider the extreme case where the sum total of government and private 
interventions eliminates all personal and community harms associated with illicit drugs, and these 
interventions need to be ongoing to contain the harms associated with drug use. In this case, we 
have expended C to save A + B. One cannot save C by spending C. 
Insert 2 provides a concrete example of this issue. Of course, there will always be examples of where 
a specific intervention replaces another on the grounds of efficiency and effectiveness. It remains 
crucial that we consider the types of questions to be answered before applying indexes such as the 
DHI to particular issues. 
New Zealand Drug Harm Index April 2016 
10 
INSERT 2. 
This insert illustrates the potential dangers of including intervention costs as a type of harm. It 
is, of course, hypothetical. 
Previous research has established that the sedative drug Stupor costs the community 
$10 million annually in personal and community harms. No attempts have been made to 
address the growing threat from Stupor to date. An innovative and ongoing programme is 
introduced that reduces the harms associated with the sedative drug by 50%. The annual cost 
of the programme is $2.5 million. Under the traditional approach, the total harm associated 
with the drug is now $12.5 million and the return on investment is $2.50 for every dollar 
invested in the programme. In reality, the actual harm avoided remains at $10 million and the 
return on investment 2:1. The traditional method overestimates the benefits associated with 
an intervention when it includes those costs as part of the harm incurred. 
The second issue is more methodological in character. The scarcity of information on harms caused 
by specific drugs is an obstacle to the development of a useful DHI. This is especially true with regard 
to new and emerging drugs, where objective information on harms is preferable to the subjectivity of 
early reports based on few cases. The pioneering efforts of Nutt et al (2010) to develop a rational 
scale to assess the harm of drugs of potential misuse is especially noteworthy. This provides a 
method, or the basis of a method, for assessing harm in the absence of other measures. The 
subjectivity of the rating can be ameliorated by aligning the relative rankings against drugs whose 
harm is already known in economic terms. 
Finally, the literature contains some hints on the characteristics of a good DHI. It is perhaps 
noteworthy that the underpinnings of the New Zealand DHI and the Australian DHI are relatively 
simple when compared to that of the UK and UNODC DHIs. Although the quest for accuracy is 
commendable, it is not always the case that increased detail will result in a commensurately 
improved model. 
As an example, imagine that we are interested in estimating the proportion of people with a certain 
physical attribute, which can be confirmed by a simple examination. For simplicity, we will assume 
that 50% of the population has the attribute. If we examined 100 people we could assume that our 
estimate was within 10% of the true value. If we examined 500 people, this reduces to 4%, which 
might be a worthwhile reduction. Boosting the sample to 1,000 people only has a marginal effect 
reducing the 4% from the sample of 500 to 3%. In short, adding numbers or complexity will very 
quickly arrive at a point where the incremental benefit may not justify the additional cost. 
Similarly, it is always tempting to include known costs because they are known, irrespective of scale. 
However, we need to consider whether the inclusion of a harm with a very marginal contribution to 
the overall estimate can be justified. 
The literature review has guided the rest of the study to adopt a combined model that used hard 
economic data where it was available and expert opinion where it was not (noting that the opinions 
will be matched against hard data where possible). The model will remain simple and be specific 
about its various uses (total harm versus intervention impact). Clear guidance will be provided on its 
update and maintenance. While the model itself is simple, it should be remembered that the 
underlying calculations are not. 
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METHOD 
This section sets out the general framework used for the research. As such, it is reliant on the earlier 
development of the New Zealand DHI and the Australian DHI. Slack et al (2008), Attewell and 
McFadden (2008) and McFadden (2006) provide more detail. The proposed method is also innovative 
in that it extends a technique developed by Nutt et al (2010) to rank drug-related harms to estimate 
in dollar terms the harm associated with new and emerging drugs. This innovation should provide 
policy makers and practitioners with an evidence base that has hitherto been lacking. This report also 
introduces a modified framework for categorising harm which explicitly states exactly who bears the 
brunt of the social costs associated with drug abuse. 
Conceptual framework 
This current study introduced a new framework for categorising harms that emphasises who bears 
the burden of illicit drug use. As discussed earlier (and repeated here for continuity of the text), costs 
were treated within the following framework: 
A. The cost of personal harm, i.e. the harms that descend upon an individual as a consequence 
of their drug use. This will comprise physical health, psychological wellbeing and personal 
wealth. 
B. The cost of community harm, i.e. the cost of crime attributable to drug use, the various 
harms to family and friends and a reduced tax base. 
C. The cost of intervention. Interventions occur as a result of attempts to address the harms 
associated with illicit drug use and include health, education and law enforcement. 
The individual costs associated with each component are generally consistent with the previous New 
Zealand and current Australian DHIs. Two significant modifications, outlined in detail below, relate to 
the inclusion of estimates of harm to family and friends and a re-evaluation of crimes attributable to 
drug use. 
The personal harms related to drug use are the drivers of all other costs. Without significant harm to 
the individual, there is unlikely to be harm to family or friends or the need for government or 
community intervention. Personal harms include poor health, injury, psychological trauma, poor 
interpersonal relationships, loss of income, loss of lifestyle, and arrest and imprisonment. The fact, 
that these outcomes can be identified as separate harms does not necessarily imply that they should 
be measured separately. Actual measures of personal harm used in this report included the cost of 
premature death and the cost of years of life lost through drug-related disability. Both these 
measures incorporate a range of personal harms (Ministry of Transport, 2014; Murray et al, 2012). 
As with Slack et al (2008), this report did not consider the potential benefits of illicit drug use. One 
would assume, given that illicit drug use is a matter of choice, that the perceived benefits must 
exceed the personal harms incurred for any rational individual. Regardless of the debate on the 
merits or otherwise of including the benefits of illicit drug use, the current approach has the 
potential to provide an approximate estimate of total harm adjusted for perceived benefits by 
eliminating some or all personal harm from the calculation of total harm. 
Community harms are the harms borne by the wider community as a result of the use of illicit drugs. 
The largest component of this traditionally has been drug-related crime. The present study 
considered new ways of estimating crime costs by distinguishing between crime committed to fund 
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drug habits and crime funded by the profits of drug trafficking. The emphasis in the literature tends 
to be on acquisitive crime to fund the drug habits. To this we have added the use of the profits of 
crime to fund further crime by organised criminal groups. This estimate utilised recent work in New 
Zealand and Australia. This category also includes an estimate of the revenue loss to the tax base 
which includes the non-payment of company tax and GST thereby reducing the revenue available to 
government to provide services. 
The other innovation in this harm type was an estimate of the pain and suffering inflicted on friends 
and relatives. Again, this is a higher-level measure that incorporates a range of specific harms. As 
noted previously, an existing body of research has indicated that this is a major contributor to the 
harm associated with drug use. 
The final category of social cost is the cost of interventions. Potentially this includes a wide range of 
government services, including: 
• education programmes to deter future drug use 
• treatment and counselling services 
• hospital admissions, emergency treatment and ambulance attendance 
• police, customs and other law enforcement activities addressing supply 
• courts and prisons. 
Strictly speaking, none of the above are harms, rather they are costs incurred in seeking to prevent 
or ameliorate the impact of drug abuse. As indicated earlier, it is reasonable to include these costs if 
we are interested in the total cost of drug abuse to the community. However, there are other 
circumstances where we might treat these categories differently. The evaluation of intervention 
strategies has already been mentioned. On a broader level, the government and the community will 
have a strong interest in knowing the harm caused by drugs (equivalent to the sum of personal and 
community harm) and what the government is investing to address the problem (equivalent to 
intervention costs). The new classification of harm and costs will make it easier to answer such 
questions. It should be noted that the cost of interventions will not include those provided by the 
private sector or charitable organisations, except where these are supported by government funding. 
Expert opinion survey 
The second innovation in the methodology is the introduction of a survey of expert opinion on harms 
associated with illicit drugs. Far more is known about the harms associated with traditional drugs 
than for newer drugs. Similarly, there tends to be more known about really harmful drugs than less 
harmful drugs. This survey provides additional information for the evidence base on illicit drugs 
where other evidence might be lacking, especially with respect to new and emerging drugs. The new 
survey differs from Nutt et al (2010) in two respects. First, it does not include legal drugs such as 
alcohol and tobacco, as these are outside the scope of this project. Second, the actual or potential 
harm in dollar terms is calculated by interpolating drugs where no estimate of economic harm exists 
between drugs of known harm, based on the relative rankings. In effect, this converts Nutt et al’s 
estimate of relative harm into an estimate of absolute harm. 
A panel of 25 experts was invited to participate. These individuals represented a diversity of 
backgrounds, providing additional strength to the survey. They included representatives from user 
groups, treatment, health, justice, police and customs. Administration of the survey was undertaken 
by the Ministry of Health. An extract from the questionnaire (Figure 1) is included for reference on 
the following page. 
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Figure 1. Extract from expert panel questionnaire on illicit drug harm 
This questionnaire is about the harm caused to an individual user. The individual could be a 
dependent user or a recreational/casual user. Each drug should be scored according to the 
following scale. 
Very low harm Low 1 Medium High Very high harm 
1 2 3 4 5 
Please enter the number corresponding to your considered view of harm in the space allocated 
below. 
Dependent user 
Drug type Personal harm Community harm 
Heroin   
Other opioids   
Sedatives   
Cannabis   
Synthetic cannabis   
Hallucinogens   
Ketamine   
Cocaine   
Ecstasy   
Methamphetamine   
Amphetamine sulphate   
Dexamphetamine   
Other stimulants   
Casual user 
Drug type Personal harm Community harm 
Heroin   
Other opioids   
Sedatives   
Cannabis   
Synthetic cannabis   
Hallucinogens   
Ketamine   
Cocaine   
Ecstasy   
Methamphetamine   
Amphetamine sulphate   
Dexamphetamine   
Other stimulants   
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There are a number of points to note about the expert panel survey. 
• First, the questionnaire does not include items relating to intervention costs. These can be 
sourced directly from the relevant agencies. 
• Second, the questionnaire is a living document. The panel has the opportunity to add or 
delete drugs from the list so that it retains its relevance. It could be extended at the panel’s 
discretion to licit drugs that cause harm. 
• Third, the survey should prove especially valuable in quantifying the potential harm of new 
and emerging drugs. As such, it could be an integral part of any early warning system. In 
fact, the use and value of the survey for other purposes have the potential to be just as 
important as its application to the Drug Harm Index. 
• Fourth, the questionnaire does not include reference to NBOMEs and other emerging 
drugs, although estimation of harm for new drugs was one of the original aims of the 
research. These were not included at this point because, as a first step, it was necessary to 
confirm the application of the new technique to known drugs. Once validated, the 
technique can be extended to other drugs. 
Prevalence versus incidence 
The majority of DHIs have used a prevalence approach to calculating harms, as is common in burden 
of disease studies. The approach is explained by Slack et al (2008): 
The prevalence approach estimates resource diverted in a given year due to the impacts of past 
and present illicit drug use. The costs estimated using the prevalence approach are then 
compared to a counterfactual situation, in this case where no illicit drugs were ever used. That is, 
in order to determine the harm avoided by reducing drug consumption we compare the current 
situation with drug use to a hypothetical case where there is no harmful drug use. ………. The 
prevalence approach has the advantage of using currently available health data, such as mortality 
and morbidity figures related to illicit drug use, to define what a counterfactual population would 
have looked like today. This is likely to result in more robust estimates than under the major 
alternative approach based on incidence. 
The claim that it results in ‘more robust’ estimates than the incidence approach is a courageous one. 
In contrast to the prevalence approach, the incidence approach uses data from a defined period 
(normally a year) to estimate harm. The preferred method will depend, first, on the question to be 
answered, and second, on variability in the data. 
The prevalence approach is primarily a historical one. It calculates the harm that could have been 
avoided had illicit drugs never existed. It answers the question ‘How much harm has historical illicit 
drug use caused?’ The alternative question is of more interest to government, policy makers, 
practitioners and the community: ‘How much harm is current drug use causing now and likely to 
cause in the near future?’ An approach based on current levels of harm is preferable for addressing 
this question. The future is more akin to the present and the immediate past rather than the distant 
past. In the present case, the incidence method is preferred. 
Nevertheless, it is true that estimates based on a single year could be subject to variability from year-
to-year. This is addressed by using averages over a number of years, where possible, and by 
comparison with alternative data sets. A modified incidence approach was used in this report as 
being more representative of the aims of this study. 
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In a steady-state world, there should be no difference between estimates based on prevalence and 
incidence. However, the world of illicit drugs is one of rapid change. 
Polydrug users 
There is an ever-present risk of double counting when considering drug use at the level of individual 
drugs. Many users consume more than one drug type, so the sum of users at the individual drug level 
exceeds the total number of drug users. Polydrug use is both complex and important. This study 
addressed the problem by adjusting the estimated user population of specific drugs by the ratio of 
the total number of individual drug users to the sum of the drug users at the individual drug level. In 
effect, this assumes that the probability of a specific drug being used in combination with another 
drug is equal for all drug types. 
It should be noted that the original version of the New Zealand DHI uses survey information, where 
available, to allocate users of two classes of drug to the class with the highest harm profile. This 
facility is not available for all drugs, and thus Slack et al’s (2008) estimates of the drug user 
population are probably overstated. It also tends to transfer harms from less harmful drugs to more 
harmful drugs, potentially skewing the distribution of results. 
Closing comment on method 
In summary, the current method included many of the building blocks used in the previous version of 
the New Zealand Drug Harm Index. There was a change to the way this material is presented. The 
base information was organised into a common-sense and practical structure of personal harm, 
community harm and intervention costs. There were changes to the content as well. Drug use affects 
not only the drug user but also their family and friends. An estimate of this harm was included in the 
revised DHI. Estimates of the harm associated with the diversion of capital into illicit drug trafficking 
have been thoroughly overhauled, especially with respect to organised crime. 
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Drug use 
The extent of drug use in society is always difficult to ascertain. The activity itself is illicit and in many 
respects constitutes a ‘victimless’ crime. The most widely used technique is the sample survey of the 
population, participation in which is voluntary and anonymity is guaranteed. Nevertheless, the 
sample survey may fail to reach a portion of the drug user population, such as the homeless and 
those in prison. Specialised surveys of particular subsets are also used, including those in treatment, 
in prison or recently arrested. 
Some indication of the variability in estimating the number of drug users can be found in Hall et al 
(2000), who used three separate methods with different multipliers to estimate the number of heroin 
users in Australia. The result for Australia ranged from 67,000 to 92,000; the median was 74,000 and 
the mean 77,000. In the calculation of overall harm or cost to the community, one of the most 
influential factors is the estimated number of drug users, and this may be subject to some variation. 
Nevertheless, given the various factors dampening the response rate to a general survey, it is safe to 
conclude that these results constitute a conservative estimate of the prevalence of drug use in the 
population. 
Prevalence of drug use 
The extent of drug use in New Zealand was estimated using data extracted from the 2012/13 New 
Zealand Health Survey. The results of that survey had not been published at the time of compiling 
this report. The design for the extract was developed by Martin Woodbridge, Ministry of Health. This 
design uses the same definition of ‘illicit drug group’ as is intended for the analysis of the 2012/13 
New Zealand Health Survey. Specific drug types were classified into drug groups as follows. 
Table 1. Illicit drug groups and corresponding drug types 
Illicit drug group Illicit drug type 
Amphetamine-type stimulants • Amphetamine 
• Methamphetamine 
• Dexamphetamine 
• Pharma-stimulants 
• Cocaine 
Cannabinoids • Cannabis 
• Synthetic cannabis 
Hallucinogenic and psychedelic drugs • LSD 
• Ecstasy 
• Ketamine 
Opioid and sedative drugs • Pharma-opioids 
• Heroin/homebake 
• Pharma-sedatives 
• GHB 
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The original New Zealand DHI classified ecstasy as a stimulant rather than among the hallucinogenic 
and psychedelic drugs. The rise of the ‘pharma-drugs’ is another significant change. A pharma-drug is 
a legal drug that has been diverted illegally to the illicit drug market. It should also be noted that the 
cannabinoids group contains both natural and synthetic cannabis. Hereafter the term ‘cannabis’ 
refers specifically to the natural product and ‘cannabinoids’ to the group. 
Note: The data were extracted for the specific requirements of the study. It is unlikely that 
the 2012/13 New Zealand Health Survey when published will correspond to the numbers 
provided here. The correction for polydrug use is the most probable source of variation 
between the data sets. The extraction of specific subsets might also contribute. 
The definition of a dependent user proposed for the 2012/13 New Zealand Health Survey was also 
adopted to ensure consistency of approach. Drug users were categorised as dependent if drug use 
was weekly or more frequent and resulted in self-reported harms. All other users were classified as 
casual. Table 2 has details of drug use by drug type in New Zealand in 2012/13. These estimates have 
been adjusted for polydrug use by applying users fractionally across drug types. Prevalence rates 
were derived from the 2012/13 Health Survey and applied to an estimated population of those 
15–75 years of age to calculate the number of users by drug type. 
Note that the reliability of estimates of the number of drug users by drug type depends on sample 
size. While this was generally not an issue at the broader level of drug category (e.g. opioids and 
sedatives), it was often an issue with specific drug types (e.g. heroin). Also note that all calculations 
were done using highest degree of accuracy possible. For example, in the following table the number 
of regular cannabinoid users was estimated at 26,021.88. This is suggestive of a degree of accuracy 
that is not possible with such data. To remove this impression of extreme accuracy, the number of 
users has been rounded to the nearest hundred. Note that rounding always takes place as the final 
operation so that totals reported may differ from the sum of constituent estimates. Nevertheless, all 
estimates are the best available given the data. 
Table 2. Estimated population by drug group, adjusted for polydrug use 
Drug group Estimated number of users 
Dependent Casual Total 
Amphetamine-type stimulants 1,400 24,300 25,700 
Cannabinoids 26,000 253,300 279,400 
Hallucinogenic and psychedelic drugs 500 53,300 53,700 
Opioid and sedative drugs 2,000 27,200 29,200 
Total 29,900 358,100 388,000 
Table 2 suggests that there were approximately 388,000 individual illicit drug users in 2012/13. This 
figure is derived directly from the Health Survey results. The number of users in each of the drug 
groups sums to a total of 532,600 users. This indicates that 37% of all users are polydrug users. For 
our purposes, a polydrug user was one who used drugs across the various drug groups. Users who 
used a number of different drugs within a group (e.g. both heroin and homebake) were not 
considered polydrug users. 
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It should be noted that the estimated proportion of polydrug users is, in fact, a ceiling based on an 
assumption that polydrug use is limited to use across two drug categories. This is almost certainly not 
the case; where an individual used three or more drug groups, the proportion of individual polydrug 
users would be less. There was insufficient data available to make an accurate assessment of the 
actual proportion of individual polydrug users. 
The following insert illustrates some of the issues relating to polydrug use. 
INSERT 3. 
Anecdotally, it would appear that dependent users are likely to be tagged as probable 
polydrug users. The results here suggest the opposite, with 50% of casual users estimated as 
polydrug users compared to 11% of dependent users. It is not clear whether this is related to 
the methodology used or whether it is a genuine finding. If this finding is confirmed by other 
studies, it has implications for our approach to polydrug use. 
Illicit drug consumption in New Zealand 
Drug consumption is even more difficult to estimate than the number of users. While the 
composition and purity of some drugs are relatively stable, this is not always the case. This is 
especially true of the ‘party drugs’ where, for example, a drug labelled ‘Ecstasy’ may in fact contain 
very little MDMA. The strength and components of the amphetamines are also known to vary. To 
maintain consistency with the previous version of the DHI, estimates of the typical amount 
consumed per occasion of use were adopted from that report (Slack et al, 2008). It should be noted 
that the current report uses a wider group of specific drug types than the 2008 report. Where drugs 
had a natural affinity, estimates of average consumption were shared. A complete description of the 
calculations and source data is provided in Attachment A. 
The results of this analysis are provided in Tables 3 and 4. The results for cannabinoids apply to dry-
leaf equivalent and for other drugs to the pure component, as per Slack et al (2008). Again, amounts 
have been rounded to avoid the impression of a highly accurate estimate. Table 3 has been rounded 
to the nearest ten except for hallucinogenic and psychedelic drugs, where the actual estimate is 
shown. Estimates for this group are influenced by the fact that the psychoactive content of a dose is 
typically small compared to other drugs. 
Table 3. Drug group, user type and total amount consumed 
Drug group Total kilograms consumed per year 
Dependent 
users 
Casual 
users 
All users 
Amphetamine-type stimulants 130 160 290 
Cannabinoids* 16,190 11,260 27,440 
Hallucinogenic and psychedelic drugs 3 21 24 
Opioid and sedative drugs 260 250 500 
* Dry-leaf equivalent. All other drug groups report pure component. 
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Table 4. Drug group and amount consumed per user 
Drug group Grams consumed per user per year 
Dependent 
users 
Casual 
users 
All users 
Amphetamine-type stimulants 90 10 10 
Cannabinoids* 620 40 100 
Hallucinogenic and psychedelic drugs 5.6 0.4 0.4 
Opioid and sedative drugs 130 10 20 
* Dry-leaf equivalent. All other drug groups report pure component. 
As expected, the cannabinoids were the principal drug group by amount consumed. The total weight 
of pure stimulants was estimated at 290 kg and of opioids and sedatives at 500 kg. The average 
consumption per user is given in Table 4, with the same rounding rules as for Table 3. 
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Drug harm calculations 
Harm calculations were made in relation to the illicit drug groups described in Table 1. As noted 
previously, harms were categorised as personal where they related to drug users themselves, and as 
community where they related to the wider New Zealand community. The cost of government 
attempts to curtail the use of illicit drugs or to moderate their harmful effects was included in 
intervention costs. As mentioned earlier, this classificatory system is introduced here for the first 
time. The new system is explicit about who suffers harm and what harms they suffer. 
Personal harms 
Personal harms included in the report include harms related to premature death and harms related 
to a reduction in the quality of life resulting from illicit drug use. 
Premature death 
The classification of cause of death is a complex matter and the method used will depend to a large 
extent on the questions to be resolved. Rather than analyse existing health records in detail, it was 
decided to exploit, if possible, existing data sources. New Zealand reports annually to the UNODC on 
a range of drug-related matters, including the number of drug-related deaths. This has the advantage 
that the definition of a drug-related death conforms to a widely accepted standard. Therefore, to 
maintain consistency with internationally agreed standards, the number of drug-related deaths was 
sourced from the UNODC drug-related mortality tables (UNODC, 2014). 
The most recent year available for New Zealand is 2010, and 75 deaths were reported. This figure is 
similar to the preliminary estimate for 2011 of 78 deaths. Cannabis, amphetamines and cocaine were 
ranked in that order as the drugs primarily responsible for these deaths. This ranking demonstrates 
that New Zealand’s illicit drug environment differs from the majority of countries where heroin is 
indicated as the primary cause of drug-related deaths. The mortality estimate is perhaps slightly 
older than is desirable. Note that the UNODC records drug-related deaths including, but not 
restricted to, overdose deaths. In the figures for 2010, 10 of 75 deaths are recorded as due to 
overdose. This is low compared to most developed nations and is indicative of the low prevalence of 
heroin in New Zealand. 
The most recent government estimate for the value of a human life is $3,948,300, based on a 
willingness-to-pay study conducted by the Ministry of Transport (2014). Estimated costs associated 
with premature death were allocated across drug groups nearly in accordance with the UNODC data. 
The 10 overdose deaths were allocated to the opioid & sedative drugs group. Of the remaining 
deaths, one was allocated to hallucinogenic & psychedelic drugs. Deaths attributable to this group 
are rare, but they do occur. The remaining 64 deaths were divided between the amphetamine-type 
stimulants group and the cannabinoids on the basis of the UNODC rankings. Attachment B has more 
detail. 
Table 6 has an estimate of harm from this source by drug group. The total cost of premature death 
was estimated as $296.1 million using 2010 deaths reported and the 2014 value of a human life. The 
amphetamine-type stimulants group and the cannabinoids each recorded values of $126.3 million. 
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Loss of quality of life 
This study took a top-down approach to the calculation of the loss of quality of life. The proportion of 
costs related to a reduced quality of life were estimated as a proportion of the costs associated with 
premature deaths. Four studies were identified for this purpose, and the results are reported in 
Table 5. Note that the proportions provided were based on data from these studies that detailed 
costs related to premature death and to loss of quality of life separately. 
Table 5. Estimated proportion of disability costs by scope and location 
Source Scope Location Proportion of disability costs 
to premature death costs 
Murray et al (2012) All disease Australasia 1.22 
Melberg et al (2011) Drugs Northern Europe 0.85 
Moore (2007) Drugs Australia 1.05 
Degenhardt et al (2013) Drugs Global 4.58 
There is general agreement between the studies that the overall cost of drug-related disability is 
nearly equivalent to the cost of premature death. Degenhardt et al (2013) is the exception with 
disability-related costs exceeding those related to premature death by a factor of 4.58. The 
Degenhardt estimate is based on a global estimate of these burdens. It is highly probable that the 
sample base of the other three studies (Northern Europe, Australasia and Australia) have a good deal 
more in common with each other than they do with a global estimate. 
It was decided to exclude the Degenhardt estimate from the final multiplier calculation, which was 
based on the average of the other three studies. The resulting multiplier was 1.03. This result is 
consistent with the Ministry of Transport’s assumption that the economic cost of loss of life is 
equivalent to that of permanent disability (Ministry of Transport, 2014). Results by drug group are 
provided in Table 6. Attachment B has more detail. 
Overall, years of life lost through disability accounted for an estimated harm of $304.8 million, the 
majority of which ($260.2 million) related to cannabinoids or amphetamine-type stimulants. 
Table 6. Personal harms by drug group 
Drug group Deaths 
per 
annum 
Premature 
death cost 
 
($m) 
Loss of 
quality of 
life* 
cost ($m) 
Estimated 
personal 
harm 
cost ($m) 
Average 
harm per 
dependent 
user cost ($) 
Amphetamine-type 
stimulants 
32 126.3 130.1 256.4 184,200 
Cannabinoids 32 126.3 130.1 256.4 9,900 
Hallucinogenic and 
psychedelic drugs 
1 3.9 4.1 8.0 17,800 
Opioid and sedative 
drugs 
10 39.5 40.6 80.1 39,600 
Total 75 296.1 304.8 601.0 20,100 
* Disability costs as a proportion of premature death costs. Multiplier is 1.03. 
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Summary and comment 
In previous versions of the DHI in New Zealand and Australia, the true cost of drug abuse to drug 
users has been obscured by the classificatory system used, which derived from cost-of-drug-abuse 
studies carried out in Australia by Collins and Lapsley (2002, 2008). The total cost of personal harm to 
drug users in New Zealand is now estimated at $601.0 million, with half of that amount due to years 
lived with a drug-related disability. Cannabinoids and ATS caused the most harm in total. The 
personal harm to individual users reveals a different story, with ATS causing the most harm at 
$184,200 per dependent user, while cannabinoids account for the least personal harm at $9,900 per 
annum per dependent user. The high overall cost associated with cannabinoids is due largely to the 
extent of consumption in New Zealand. Later the results of the expert panel will suggest that there 
are significant differences between social costs associated with natural and synthetic cannabis. 
The apportioning of all personal harms solely to dependent users is worthy of comment. There is a 
small amount of personal harm incurred by casual users; however, this amount is almost negligible in 
relation to the harms casual use inflicts on the broader community (this will be the subject of later 
discussion). Rather than make an unreliable estimate of a minor cost, it was decided to fold these 
costs into those incurred by dependent users. 
Community harms 
Community harms occur in different domains. First, there are specific harms that affect the family 
and friends of drug users. The current revision of the DHI is the first published DHI to include this 
cost. Second, there are a variety of harms that follow drug-related crime, including acquisitive crime 
by drug users to fund drug purchases, and the reinvestment of profits in a wider range of crimes to 
assist in the diversification of criminal enterprises. Third, there are harms caused by a reduced 
revenue base to the government. The sale of illicit drugs is not subject to GST, and organised crime 
does not pay company tax on its profits. The reduced tax base means fewer funds are available for 
services such as health, education and infrastructure spending. 
Family and friends of drug users 
Traditionally, the literature, including advice from a range of organisations, tends to focus on the role 
of family and friends as a conduit to alleviating or ameliorating the harms experienced by drug users. 
Intuitively one would think that family and friends would be significantly affected by the experience 
of a friend or family member who has a drug problem. There is a limited literature on the topic as 
well as recent evidence of renewed interest in this issue (Shanahan et al, 2015). 
Nevertheless, in previous versions of the DHI, the harm to family and friends was largely absent and 
what was included was hidden within other categories. There is reason to believe that the harm 
experienced by family and friends is an important issue in its own right. Melberg et al (2011) 
conducted a representative survey of 3,092 adults in Copenhagen, Helsinki, Oslo and Stockholm. 
Almost half of the respondents had at some time known and been concerned about the drug abuse 
of a personal acquaintance (i.e. family or friend). In Oslo, 14% of respondents indicated that they 
were willing to pay for the treatment of a friend. In fact, median responses across all respondents 
ranged from 500 euros for a friend to 13,000 euros for a child. 
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It is argued that the amount family and friends are willing to pay is closely related to the personal 
harm or distress that family and friends experience as a result of another’s drug habits. While a 
proportion of respondents willing to pay for treatment might be acting entirely from altruism, 
indications from the Melberg et al study indicate that there are significant harms experienced by 
family and friends, with 6.5% reporting they had feared violence from the drug user and 22.5% 
acknowledging they had been worried in the past 12 months. From these figures it would appear 
that willingness to pay and incurred harm may be closely related. It is noted that the extent of the 
impact altruism has on the final estimates is probably more than compensated for by conservative 
estimates of other key variables described in the following paragraph. 
The current measure assumed that the proportion of the adult population willing to pay for 
treatment for friend or family was the same in New Zealand as in Norway. This assumption is 
conservative, as New Zealand’s adult population has a higher proportion of current drug users than 
Norway’s. It was also assumed that the average willingness-to-pay figure for family and friends was 
500 euros. Again this was a conservative figure given the range of 500 to 13,000 euros in the Melberg 
study. The number of family and friends willing to pay 500 euros each was calculated as 14% of the 
adult New Zealand population in 2014. 
It was also assumed that drug users causing significant harm to family and friends would be 
dependent users. The results were converted to New Zealand dollars and adjusted by the Consumer 
Price Index to allow for an increase in costs since the time of the study. 
The results are reported in Table 7. Estimated harm was distributed by drug group according to the 
number of dependent users in each. This method assumes that the number of family and friends 
involved is constant across drug groups. As such, the annual harm per dependent user is $14,600 
regardless of the drug of abuse. 
Table 7. Estimated harm to family and friends by drug group 
Drug group Number of 
dependent 
users 
Estimated number 
of family and 
friends 
Estimated 
harm 
($m) 
Amphetamine-type stimulants 1,400 19,200 20.4 
Cannabinoids 26,000 359,400 380.9 
Hallucinogenic and psychedelic drugs 500 6,200 6.6 
Opioid and sedative drugs 2,000 28,000 29.6 
Total 29,900 412,700 437.5 
The economic value of the harm experienced by the family and friends of frequent drug users is 
$437.5 million. This is the largest single category of harm identified in this study and has not been 
previously reported in the literature. Note that this report did not take into account one significant 
family relationship: children. The children of drug users, especially dependent drug users, are subject 
to a variety of harms. There is insufficient information available to allow an estimate of the social 
cost borne by children of drug users. 
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Acquisitive crime 
Acquisitive crime as a means of funding illicit drug purchases has long been assumed and long been 
hotly debated. It is a difficult area. For example, based on figures for the UK DHI (Goodwin, 2007), 
acquisitive crime accounted for 61.9% of the 2005 index. In contrast, figures from Slack et al (2008) 
suggest that property losses accounted for 6.1% of the NZ DHI. There are obviously differences in 
method, but it is cautionary to observe that under two separate measures of drug harm the relative 
contribution of property crime can differ tenfold. 
The community tends to be more certain about the link between drugs and crime. It is a commonly 
held community belief that many dependent drugs users fund their habit through acquisitive crime. 
A Ministry of Health survey of community attitudes to illegal drugs provides examples of this: 
Illegal drug taking to excess was associated with criminal behaviour and also generally becoming 
more financially stressed with the need to fund the drug habit. 
• That’s when they start burglaring and bashing people just to get what they want. (Napier, 
parents of Year 7 and 8 children, female) 
• And breaking into everybody’s cars and getting their stereos and what not and selling them 
off on the market. (Napier, parents of Year 7 and 8 children, female) 
• Socially it can destroy you because you have to fork out all your money to get more of this. 
Eventually you have to go and slum and steal. (Christchurch, 17–18 years, male) 
• I guess it ends up in committing more crimes to pay off stuff for P and those things. 
(Auckland, Māori, student, 18–24 years, male) 
(Ministry of Health, 2009, p.43) 
The evidence from the literature is quite different. Stevens (2008) traced the development of the 
political debate in the UK over drugs and crime and concluded that this link had been exaggerated. 
Bryan et al (2013) conducted a recent and detailed survey of the links between heroin use, cannabis 
only use and crime. They reported that while heroin use was related to the incidence of acquisitive 
crime, cannabis use was not. Furthermore, they noted that 43% of acquisitive crime by heroin users 
was related to the need to buy drugs. The fact that illicit drug users may be implicated in acquisitive 
crime is not evidence that that these crimes were committed for the purpose of purchasing drugs. 
Caulkins and Kleiman (2011) have covered the complexities of this area. 
A secondary concern relates to the extrapolation of rates of involvement of drug users in resolved 
acquisitive crime to unresolved crime. For example, in 2014 nearly 20% of 175,000 acquisitive crimes 
reported in New Zealand were resolved (based on figures provided in Attachment B). According to 
Bryan et al (2013), the proportion of individuals committing acquisitive crime while under the 
influence of drugs ranges from 52% in the case of heroin to 9% in the case of cannabis. It is perhaps a 
reasonable assumption that impaired individuals will be more likely to leave behind evidence of their 
identity and more likely to be detected in the act. Thus, the rate of drug involvement in resolved 
crimes may overestimate the rate of involvement in unresolved crimes. (This cannot be proven, as 
unresolved crime by definition has no known perpetrator.) 
In a complex situation the following method was employed. The number of acquisitive crimes, the 
average property cost per crime and the proportion of arrestees dependent on drugs were derived 
from New Zealand sources. The proportion of arrestees who used major drugs in the past 12 months 
and claimed to be dependent (30% of arrestees) during that time was used as an indicator of the 
extent of drug-related acquisitive crime. Attachment B has more detail. The results are given in 
Table 8. 
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Table 8. Estimated cost to the community of drug-related acquisitive crime 
Drug group Number of 
dependent 
users 
Estimated 
harm 
$m 
Cost per 
dependent 
user $ 
Amphetamine-type stimulants 1,400 32.6 23,400 
Cannabinoids 26,000 63.9 2,500 
Hallucinogenic and psychedelic drugs 500 1.9 4,200 
Opioid and sedative drugs 2,000 41.4 20,400 
Total 29,900 139.7 4,700 
The economic value of property lost as a result of acquisitive crime committed to fund drug use is 
$139.7 million. It was also assumed that acquisitive crime was committed by dependent users and 
not casual users. The cost per user was estimated at $4,700 for all dependent users. It is estimated 
that dependent users of amphetamine-type stimulants had the highest level of drug-related crime by 
value at $23,400 per user; this was strongly driven by the results for methamphetamine. This was 
followed by users of opioid & sedative drugs at $20,400. 
Organised crime 
Organised crime plays a significant role in drug production, importation and distribution. The 
majority of harms relating to drug trafficking are drug-related and dealt with in the other sections of 
this report. This section is concerned with harms that actually extend beyond the harms traditionally 
associated with illicit drugs. In part, this is due to the evolution of organised crime structures and to 
the diversification of business. Organised crime acts like legitimate business in attempting to lower 
the risk associated with activities. One strategy to reduce risk is diversification. 
Drug crime is highly profitable but not all profits of crime are reinvested in crime. Recent work 
(McFadden, 2015) undertaken on behalf of the New Zealand Police suggests that 56% of the revenue 
from drug trafficking is reinvested in criminal activity, while the remainder is used to support a 
lifestyle. The majority reinvested will fund further drug trafficking; however, some will be invested in 
other activities such as extortion, fraud, pornography and weapons trafficking. (Insert 4 provides an 
interesting example of the link between illegal fishing and drugs.) The exact proportion invested 
elsewhere is difficult to estimate. 
Hughes et al (2015) provided a network analysis of the links between major drug crimes and other 
types of crime in Australia. They found that 28.5% of cases in the linked network were not drug-
related and that the majority of cases were associated with economic crime. There is insufficient 
information available to calculate the actual proportion of profits from drug trafficking reinvested in 
other crime. Based on the Hughes et al figures it is unlikely to exceed 28.5%. A conservative estimate 
of 20% was used in the model. Thus, the proportion of drug-related revenue reinvested in other 
crime is 20% of 56%, or approximately 11%. More detail on the method employed is provided in 
Attachment B. The results are provided in Tables 9 and 10. 
New Zealand Drug Harm Index April 2016 
26 
Table 9. Reinvestment in organised crime by drug group and user type 
 Expenditure on illicit drugs ($m) Reinvestment in organised crime ($m) 
Drug group Dependent Casual Dependent Casual Total 
Amphetamine-type 
stimulants 
34.0 42.4 3.8 4.8 8.6 
Cannabinoids 323.7 225.1 36.3 25.2 61.5 
Hallucinogenic and 
psychedelic drugs 
0.2 1.6 0.02 0.2 0.2 
Opioid and 
sedative drugs 
1.0 1.0 0.1 0.1 0.2 
Total 358.9 270.1 40.2 30.3 70.4 
Over $70 million in funding for other criminal activities is provided each year from drug trafficking. 
The majority of this (nearly 90%) is generated from the sale of cannabinoids. The indirect funding of 
other criminal activity touches all drug users. In general, the casual user does not face the range or 
intensity of harms endured by dependent users. Nevertheless, the casual user makes a significant 
contribution to the expansion of criminal activity beyond drug trafficking and into other forms of 
crime. Over $30 million derived from the profits of sales of illicit substances to casual users is used 
annually to fund a diverse range of crimes. This is over 40% of all non-drug criminal activity derived 
from the profits of drug trafficking. 
INSERT 4. 
http://www.fish.govt.nz/mi-nz/Press/Recidivist+paua+poacher+sentenced+on+poaching+and+drug 
Recidivist paua poacher sentenced on poaching and drug charges 
9 November 2012 
A fifty-four-year-old Upper Hutt man was sentenced in the Wellington District Court yesterday for his 
role in a black market paua ring and for methamphetamine offences. Saravuthy Mao was sentenced 
on all charges to five years and three months imprisonment and banned from fishing for three years. 
Mr Mao was the ringleader for a group that poached paua from the Wellington coastlines between 
January and March 2010. The illegal paua was on-sold into the Auckland Asian community and 
restaurants. Mr Mao committed these offences while on parole from prison for past poaching 
offences. During late 2010 Mr Mao was identified as the leader of a poaching ring which included his 
associate Ronald Daly. In early 2011, fishery and police officers executed a search warrant at an 
Upper Hutt property and found scales for measuring methamphetamine, $16,135 cash, and 
6.7 grams of methamphetamine. A further $13,770 cash was later located at the address of another 
associate, Harlee Watene. Ministry for Primary Industries (MPI) Manager – Operational Support Unit, 
Gray Harrison says the case was a MPI and Police combined effort. “The outcome of this case is a 
great example of inter agency co-operation on the frontline. It highlights what can be achieved by 
dedicated staff intent on apprehending offenders who compromise the sustainability of our fisheries 
and at the same time engage in serious drug offending,” says Mr Harrison. 
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Table 10. Reinvestment in organised crime per user 
 Number of users Reinvestment in organised crime per user $ 
Drug group Dependent Casual Dependent Casual All users 
Amphetamine-type 
stimulants 
1,400 24,300 1,200 200 300 
Cannabinoids 26,000 253,300 300 200 200 
Hallucinogenic and 
psychedelic drugs 
500 53,300 > 20 > 20 > 20 
Opioid and sedative 
drugs 
2,000 27,200 > 20 > 20 > 20 
Total 29,900 358,100 300 100 200 
The preceding analysis and estimates relate to the reinvestment of drug trafficking profits into other 
illegal activities. There is a further threat posed by drug trafficking profits entering the legitimate 
economy as organised crime seeks to diversify further by investing in legitimate business. This is in 
addition to any money laundering activities. 
This is not a new problem. McDowell and Novis (2001) describe the negative impacts of criminal 
profits being invested in the legitimate economy as: 
• undermining the private sector by subsidising legitimate business with drug profits, thereby 
creating a competitive advantage over honest businesses 
• undermining the integrity of financial markets by moving large sums of money through the 
international financial system 
• loss of economic control that the previous point entails, especially to developing economies 
• the economic damage that ensues from the perception that countries are corrupt and 
involved in the laundering of drug profits. 
These threats are less likely to occur in countries with strong institutions, transparent government 
and appropriate checks and balances in place. Nevertheless, there has been concern in a number of 
developed countries about the growing threat to small business and recently the property market 
associated with the business diversification strategy of organised crime. No attempt was made to 
include a current estimate of these costs on the New Zealand economy due to the size of that task. 
Government and policy makers should be aware that drug trafficking is one of the primary sources of 
funds used by organised crime to diversify into legitimate business. 
Reduced tax base 
A further aspect of the economic harm associated with organised crime’s involvement in drug 
trafficking is the loss to the tax base available to the government. Modern organised crime will seek 
to lower its risk through diversification and enhance its profitability by tax avoidance. Organised 
crime generally pays neither GST nor company tax. In doing so, it reduces the government’s ability to 
provide services to the people of New Zealand. Table 11 has details of tax avoided by drug group and 
source of income. 
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Table 11. Tax avoided by organised crime by tax type and source of income 
Tax type Drug group Income derived 
from dependent 
users: 
tax avoided ($m) 
Income derived 
from casual 
users: 
tax avoided ($m) 
Income from 
all users: 
 
tax avoided ($m) 
GST Amphetamine-type 
stimulants 
4.2 5.3 9.5 
Cannabinoids 40.3 28.0 68.3 
Hallucinogenic and 
psychedelic drugs 
0.02 0.20 0.22 
Opioid and sedative 
drugs 
0.13 0.12 0.25 
Total 44.7 33.6 78.3 
Company Amphetamine-type 
stimulants 
9.0 11.3 20.3 
Cannabinoids 86.0 60.0 145.8 
Hallucinogenic and 
psychedelic drugs 
0.05 0.42 0.47 
Opioid and sedative 
drugs 
0.27 0.26 0.53 
Total 95.3 71.7 167.1 
All taxes Amphetamine-type 
stimulants 
13.3 16.5 29.8 
Cannabinoids 126.3 87.8 214.1 
Hallucinogenic and 
psychedelic drugs 
0.07 0.62 0.70 
Opioid and sedative 
drugs 
0.40 0.38 0.78 
Total 140.0 105.4 245.4 
The basis of this measure was the income derived from drug trafficking, as it was for the estimate of 
organised crime’s reinvestment in other crime. An accurate assessment of GST would be based on 
revenue less any GST credits. With an illegal enterprise such as drug trafficking, it is difficult to 
estimate the extent of GST credits. As an alternative and conservative estimate, GST was calculated 
against estimated profit, as company tax properly is. Tax avoided was calculated by multiplying 
estimated profit by income by the GST rate of 15% and by the company tax rate of 32%. McFadden 
(2015), using New Zealand Police data, estimated that drug-related revenue included 83% profit, 
with the remaining 17% reimbursing the costs of running the business. 
Overall, $245 million is lost to the tax base through the failure to pay appropriate taxes in relation to 
revenues and profit generated by illegal drug trafficking. Naturally, given the illicit nature of drug 
trafficking, this additional revenue could only be realised either by the legalisation of illegal drugs or 
by the diversion of this investment into legal forms of investment. Nevertheless, it remains a genuine 
social harm associated with illegal drug trafficking. 
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Summary 
The community harms reported above are numerous and the accompanying tables complex. 
Table 12 has the detail of cost summarised at a higher level. 
Table 12. Summary of specific community harms by drug group ($ million) 
Drug group Family and 
friends 
Acquisitive 
crime 
Organised 
crime 
Reduced 
tax base 
Total 
Amphetamine-type 
stimulants 
20.4 32.6 8.6 29.8 91.4 
Cannabinoids 380.9 63.9 61.5 214.1 720.3 
Hallucinogenic and 
psychedelic drugs 
6.6 1.9 0.2 0.70 9.0 
Opioid and sedative 
drugs 
29.6 41.4 0.2 0.78 72.0 
Total 437.5 139.7 70.4 245.4 892.7 
In total, the cost to the community of harms associated with drug abuse was $892.7 million in 2014, 
which exceeds the collective harms to the drug users themselves ($601.0 million). The single largest 
contributor to this result was harm to family and friends at $437.5 million. There is at least a 
suggestion that more attention could be given to this group. Whether that is required or not is 
difficult to assess as this group collectively is probably more interested in the outcomes for drug 
users. Certainly, information on harm to family and friends is largely absent from public statistics 
globally. 
The contribution of crime in its various forms is also significant, accounting for another 
$455.2 million. The role income from drug trafficking plays in a wider network of crime is almost 
certainly underestimated. On the other hand, tax avoided in terms of GST or company tax is unlikely 
to be recovered in full under any circumstances. Nevertheless, it remains a quantifiable source of 
harm to the community. 
Cost of interventions 
The report so far has been concerned with the harms to both users and the community that can be 
attributed to drug use. As noted earlier, traditionally the costs of treatment, law enforcement, courts 
and corrections have been included somewhat indiscriminately with the direct harms caused by drug 
use. This has the unfortunate implication that costs associated with addressing the problem become 
part of the problem itself. 
It was argued earlier that a proper analysis of the social costs of illegal drugs will distinguish between 
the actual harms and attempts to address them. It had been intended to estimate the cost of 
intervention according to the class of intervention, including: 
• education programmes to deter future drug use 
• treatment and counselling services 
• hospital admissions, emergency treatment and ambulance attendance 
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• police, customs and other law enforcement activities addressing supply 
• courts and prisons. 
At this point, however, it is not possible to distribute costs across this framework. As an alternative, 
the traditional activity-based methods of allocating intervention costs against the sponsor agency 
was used. Complications remained. Many interventions are general and do not target specific drug 
types. In fact, a number of interventions address alcohol, tobacco and illegal drugs under the one 
programme. On the other hand, some programmes are drug specific, but it is difficult to draw strict 
boundaries and the problem remains: what to do with general intervention costs? 
It would appear from discussions with agency representatives that general interventions are more 
common than drug-specific ones. This is especially true of activities that are preventive or 
educational, or more broadly based on lifestyle or community. Given that the majority of harms 
accrue to dependent users, it was decided to allocate intervention costs to drug groups by the 
number of dependent users. This approach is based on expediency given the general nature of much 
of this work. 
The Ministry of Health, New Zealand Police, Customs and Corrections were approached to provide 
direct estimates of their expenditure on drug-related issues. Court costs were calculated by 
estimating the proportion of appearances before court where illicit drugs or drug-related acquisitive 
crime were the principal offence. (See ‘Acquisitive Crime’, above, for details of the estimation of 
drug-related cases.) This rate was applied to the 2014/15 court budget. Table 13 has details of costs 
by government agencies. The total cost of interventions was $351.4 million. In effect, the 
government has invested this amount in addressing a problem that causes $1.5 billion of harm to the 
community each year. 
Table 13. Cost of intervention by drug group and intervention type ($ million) 
Drug group Health Police/ 
Customs* 
Courts/ 
Corrections 
Total 
Amphetamine-type stimulants 3.6 4.8 52.1 16.4 
Cannabinoids 68.2 89.8 108.5 305.9 
Hallucinogenic and psychedelic 
drugs 
1.2 1.6 3.0 5.3 
Opioid and sedative drugs 5.3 7.0 6.3 23.8 
Total 78.3 103.1 170.0 351.4 
* Customs estimates are not available at this point. 
These figures should be treated as preliminary. In the long term, it is hoped that a more uniform and 
centralised method of reporting intervention costs can be developed. 
INSERT 5. 
The interaction between agencies and the type of intervention is nicely illustrated in the case 
of Corrections. Corrections spend approximately $5 million each year on rehabilitation and 
treatment programmes for those serving custodial and non-custodial sentences. 
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Expert evaluation 
The method relating to the expert panel has been described above. In all, 25 identified experts in the 
field were approached to participate. One declined to participate, 12 responded and 12 failed to 
respond. The questionnaire was, to some extent, exploratory and there is the potential to build a 
more substantial survey from these beginnings. 
Participants were asked to rank drugs listed in the 2012/13 Heath Survey for both dependent and 
casual users according to the following scale: 
1 Very low harm 
2 Low 
3 Medium 
4 High 
5 Very high harm 
Averages for personal and community harms were calculated separately and in aggregate for both 
dependent and casual users. In addition, expert rankings were correlated with drug harms known 
from other sources. Overall, the results are similar to those reported elsewhere in this report. The 
two figures on the following page have details of the results. 
Methamphetamine was ranked as the most harmful drug for dependent users, followed closely by 
heroin/homebake. Methamphetamine was ranked as being responsible for high to very high harm 
for dependent users. Ecstasy and LSD were ranked as contributing a lower level of harm to 
dependent users, with a median ranking of medium harm. Harms were generally lower for casual 
users. 
Rankings for personal harm tended to be higher than those for community harm. This differs from 
the harms assigned in this report. Note that the report includes several harms that have not been 
previously reported, and that these all relate to community harms. 
The primary purpose of including the expert panel was to provide estimates of harm for individual 
drugs that have not been reported on directly in this report. This has been done for specific drugs in 
the 2012/13 Health Survey. The process involved calculating harm for specific drug types where this 
was not known by interpolating points between known values using the relative rankings. The known 
social cost per dependent and casual drug user for each drug group used in this report was assigned 
to the major drug in that class. Thus, the social cost for amphetamine-type stimulants was assigned 
to methamphetamine, that for the cannabinoids to cannabis, hallucinogenic and psychedelic drugs to 
Ecstasy, and opioid and sedative drugs to the pharma-opioids. 
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Figure 2. Expert rankings of personal and community harms for dependent users 
 
Figure 3. Expert rankings of personal and community harms for casual users 
 
The results are presented in Table 14 by drug user type. Note that drug types with a known value are 
shown in bold. Intervention costs have been included in the social cost estimates. Total harm and 
social cost are equivalent for casual users because intervention costs, as mentioned earlier, were 
distributed against dependent users only. Figures have been rounded. There was a reasonable fit 
between the rankings and known values for dependent users. The fit for casual users was not quite 
as close, perhaps reflecting the difficulty in assessing harm where the level of harm is low. The 
procedure for interpolating results could be developed further. 
Overall, the results would appear to validate the use of this method, although further fine tuning is 
recommended, mainly with respect to technical issues. Now that a baseline has been successfully 
established, the method can be used to derive estimates for NBOMEs and other emerging drugs. 
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Table 14. Estimated social cost and total harm per annum by drug user and specific drug type 
 Dependent Casual 
Drug type Harm 
ranking 
Total 
harm per 
user 
Social 
cost per 
user 
Harm 
ranking 
Total 
harm per 
user 
Social 
cost per 
user 
Methamphetamine 4.3 111,300 116,600 2.9 8,300 8,300 
Heroin/homebake 4.1 98,600 104,000 3.2 9,300 9,300 
Pharma-opioids 3.3 38,300 44,300 2.5 3,200 3,200 
Cocaine 3.3 36,200 42,300 2.1 2,700 2,700 
Synthetic cannabis 3.2 35,900 42,000 2.2 2,800 2,800 
Pharma-sedatives 3.0 31,800 38,200 2.0 2,600 2,600 
Amphetamine 2.9 31,000 37,500 1.8 2,500 2,500 
Dexamphetamine 2.7 27,000 33,600 1.8 2,400 2,400 
Ketamine 2.7 26,200 32,900 1.8 2,500 2,500 
GHB 2.6 25,400 32,100 2.0 2,600 2,600 
Pharma-stimulants 2.6 24,600 31,400 1.6 2,200 2,200 
Cannabis 2.5 22,100 29,100 1.5 2,100 2,100 
LSD 2.3 4,700 6,200 1.6 2,200 2,200 
Ecstasy 2.3 4,700 6,200 1.5 400 400 
Table 14 represents the preliminary findings of a new method, so caution is advised in using these 
estimates. More detail of the method is available from the author. 
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Main results 
This section summarises estimated drug-related costs incurred by drugs users and the community in 
2014 dollar figures using the most recent data available. Note that these tables relate to the total 
social cost and include the costs of interventions. 
Table 15. Summary of social costs, by drug group ($ million) 
Drug group Personal harm 
($m) 
Community 
harm ($m) 
Intervention 
costs ($m) 
Total social 
costs ($m) 
Amphetamine-type 
stimulants 
256.4 91.4 16.4 364.2 
Cannabinoids 256.4 720.3 305.9 1,282.6 
Hallucinogenic and 
psychedelic drugs 
8.0 9.0 5.3 22.3 
Opioid and sedative drugs 80.1 72.0 23.8 175.9 
Total 601.0 892.7 351.4 1,845.0 
Table 16. Summary of social costs per kilogram of illicit drug by drug group 
Drug group Personal  
harm ($) per kg 
Community 
harm ($) per kg 
Intervention 
costs ($) per kg 
Total social 
costs ($) per kg 
Amphetamine-type 
stimulants 
872,000 311,000 56,000 1,239,000 
Cannabinoids 9,000 26,000 11,000 47,000 
Hallucinogenic and 
psychedelic drugs 
334,000 375,000 221,000 929,000 
Opioid and sedative 
drugs 
160,000 144,000 48,000 352,000 
Table 17. Summary of social costs by user type 
Drug group Total cost ($m): 
dependent use 
Total cost ($m): 
casual use 
$ cost per 
dependent user 
$ cost per 
casual user 
Amphetamine-type 
stimulants 
162.3 201.9 116,600 8,300 
Cannabinoids 756.5 526.1 29,100 2,100 
Hallucinogenic and 
psychedelic drugs 
2.8 19.5 6,200 400 
Opioid and sedative 
drugs 
89.7 86.2 44,300 3,200 
Total 1,011.3 833.7 33,800 2,300 
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Future directions 
The information relating to the type and extent of drug use and its subsequent harms is complex and 
subject to change. The main obstacle, both in New Zealand and globally, to the development of best 
practice interventions and evidence-based policy is the lack of available and valid data sets. This 
contrasts with the situation in road safety, for example, where the dimensions of the problem can be 
framed and the effect of interventions tested. It is suggested that this difference is influenced by two 
principal factors. 
1. Drug trafficking is illegal. Collecting information on drug prevalence is an attempt to gauge 
an illegal activity and, as with all illegal activities, there are obvious barriers to this 
collection. 
2. Transport and road safety is a reasonably homogeneous activity. Responsibility for drug 
practice and policy is spread over a number of agencies. 
It should be emphasised that much has been achieved. The establishment of the National Drug 
Intelligence Bureau ensures that information collection and sharing is coordinated across agencies. 
There are well-established surveys, and there are relevant data sets held by the Ministry of Health 
and others. Appropriate coordinating committees are in place and meet regularly. It should also be 
noted that the New Zealand data collections are excellent by world standards. 
A number of specific recommendations follow. (It is recognised that competing priorities may claim 
precedence over the following.) 
• The survey of illicit drug use conducted by the Ministry of Health is a key source of 
information. The period between surveys is currently five years. The cost of the survey is 
doubtless a consideration. It would be useful to have a restricted set of data collected in 
between full surveys. This interim survey could focus solely on drugs in use and frequency 
of use and be part of a wider survey to contain costs. Questions dealing with new and 
emerging drugs should be included. Consideration could also be given to allocating 
additional sources to allow the dissemination of findings at an earlier date than is the 
current practice. If adopted, this proposal would ensure the timely and regular reporting of 
information crucial to policy development and evaluation. 
• The use of the DHI as an indicator of the benefits of a programme should be made best 
practice, or even mandatory, for government-funded research and evaluation. Evaluations 
of current or proposed interventions typically involve an estimate of both the costs and 
benefits involved. The use of the DHI to measure benefits will assist in improving the 
comparison between various options by providing a common measure. It is not intended to 
restrict evaluation to the DHI alone. The DHI cannot encompass all possible benefits, and 
other measures of success are not only advisable but necessary. 
• For some agencies, the estimation of drug-related costs was difficult. Part of the problem is 
that agency costs in relation to illicit drugs are included with other harmful (yet legal) drugs 
such as tobacco and alcohol. Although recognising the cost involved in altering systems, it 
would be advantageous, at least at the agency budget level, to have funding related to illicit 
drug programmes and activities separately identified. 
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• The expert panel has the potential to be used for purposes beyond those required for the 
DHI. It could be a useful tool in any early warning system for new and emerging drugs, 
especially for estimating the potential size of the problem should a new drug gain wider 
acceptance. Responsibility for the ongoing support of the survey should be firmly 
established in an existing agency unit. 
• The identification of the harm caused to the family and friends of drug users is an important 
development. The figure is conservative so the actual harm could be much higher. It is also 
heavily dependent on a Scandinavian estimate. A partial replication of the Melberg et al 
(2011) study would confirm the actual extent of harm to family and friends in New Zealand. 
Suitable questions could form part of the next Health Survey. 
• There are some concerns over the expansion of organised crime into a variety of activities. 
It would be advantageous to develop a more accurate estimate of the amount of drug-
related revenue organised crime invests in other crime types and in legal enterprises as part 
of its diversification strategy. 
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Practical applications 
This section provides a commentary on practical applications of the DHI. 
It should be remembered that on page 2 of this report the following prescription for the revised DHI 
was given (it is repeated here for ease of reference). 
Development of a new Drug Harm Index and the associated report should assist agencies assess 
the costs and benefits of their current interventions; assist agencies evaluate how effective they 
have been in achieving the aims of the National Alcohol and Other Drug Policy; alert policy 
makers to the cost of harms associated with new drugs that have been introduced or are 
becoming more prevalent; help guide future enforcement activities and harm reduction 
strategies; and to inform future advice about how best to manage a reduction in harm caused by 
illicit drugs. 
The primary purpose of the revised DHI is to provide an evaluation tool for agencies. The DHI is only 
part of the evaluation equation. To estimate the benefits in dollar terms of an intervention, the 
reduction in consumption of illicit drugs that follow the intervention is also required. The two steps 
have tended to be conflated in previous research. Any practical application of the DHI requires an 
equally rigorous method for determining the resulting reduction in consumption. 
It should also be noted that any evaluation is strengthened by the use of multiple measures. The DHI 
provides a good basis for comparing the value of different interventions, while evaluations specific to 
the intervention under study provide deeper insights into how and why a particular intervention 
works. It is recommended that in estimating the benefits of an evaluation, the benefits should be 
restricted in most cases to personal and community harms. Intervention costs are of interest if the 
purpose of the study is to identify the total cost to the community or where there are reasons to 
believe the proposed intervention will eliminate the need for one or more existing interventions. 
The next purpose is to alert policy makers to the potential harms of new drugs. The revised DHI again 
provides a level playing field and the expert panel survey an innovative method for achieving this 
end. The DHI provides a formal process for evaluating the harm of new drugs, and it is highly relevant 
to the success of this method that appropriate administrative support for this process is in place. 
Also relevant to this purpose is the transparent and modular design of the revised DHI. The model for 
producing DHI estimates by drug type, drug group, type of harm and user group is transparent. This 
structure will allow the addition of new drugs and the revision of data relating to existing drugs on an 
ongoing basis. The revised DHI should therefore retain its currency over time. Again, the provision of 
adequate administrative support is required. 
The currency of the DHI is also relevant to the final objective, the guidance of future policy and 
practice. The DHI should assist on a number of fronts. First, it should assist in identifying what has 
worked and what has not. Second, it should identify trends in overall harm, whether the problem is 
increasing, decreasing or static. Third, it should show the trend in specific harms; for example, 
whether the personal harms associated with drug use are falling while the harms associated with the 
involvement of organised crime in drug trafficking are increasing. Finally, it should provide greater 
insight into the complex and rapidly evolving world of illicit drug use. 
  
New Zealand Drug Harm Index April 2016 
38 
Recommendations 
The following recommendations are made: 
• The economic estimates of harm related to drug use be adopted as the basis for a revised 
DHI. 
• The new classification system of personal harms, community harms and intervention costs 
be adopted for the reporting of results. 
• An ongoing and appropriately supported expert panel on drug harm be established to 
provide feedback through a regular survey of drug harms. 
• Consideration should be given to the matters raised in the Future Directions and Practical 
Applications sections of the report. 
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Attachment A: Calculation of prevalence of drug use 
Sources of data 
Aggregated information was extracted from the Drug Use module from the 2012/13 New Zealand 
Health Survey by the Health and Disability Intelligence Unit, Ministry of Health. 
Ad hoc request number Request title 
2015 134 New Zealand Drug Harm Index 2015 (NZDHI 2015): Advice on 
development of Drug Harm Index and data extraction from NZHS 
2012/13 for drug use prevalence and harms 
Information relating to consumption was sourced from: 
Moore T (2007). Working estimates of the social cost per gram and per user for cannabis, cocaine, 
opiates and amphetamines, Drug Policy Modelling Program Monograph 14, Turning Point. 
Slack A, O’Dea D, Sheerin I, Norman D, Jiani Wu & Nana G (2008). New Zealand Drug Harm Index, 
BERL report for the New Zealand Police. 
Adjustment for polydrug use 
Reference Drug group Weekly or 
more 
Less 
often 
Total 
IndATSLeastWkDenUsePYr 
/IndATSLessWkDenUsePYr 
Amphetamine-type 
stimulants 
3,400 34,000 37,400 
IndCanoidsLeastWkDenUsePYr 
/IndCanoidsLessWkDenUsePYr 
Cannabinoids 130,000 244,000 374,000 
IndHallPsyLeastWkDenUsePYr 
/IndHallPsyLessWkDenUsePYr 
Hallucinogenic and 
psychedelic 
1,900 78,000 79,900 
IndOpoidSedLeastWkDenUsePYr 
/IndOpoidSedLessWkDenUsePYr 
Opioid and 
sedative 
7,300 34,000 41,300 
 Calculated total 142,600 390,000 532,600 
There are 532,600 estimated users of the four individual drug groups, the number of unique 
individuals is lower. The following table provides the number of unique individuals. 
Reference Drug group Weekly or 
more 
Less often Total 
Ind4DrugsLeastWkDenUsePYr 
/Ind4DrugsLessWkDenUsePY 
All groups 
combined 
128,000 260,000 388,000 
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The number of unique persons was 388,000 of whom 128,000 used drugs at least weekly and 
260,000 less often. The individual drug group estimates were adjusted by the overall rate of unique 
individuals to total respondents (highlighted above). This assumes that the probability of polydrug 
use is equal across users and drug group. For our purposes, the use of multiple drugs within a drug 
group was not considered to represent polydrug use. The estimated number of unique individuals for 
each drug group is provided below. 
Drug group Weekly or more Less often Total 
Amphetamine-type stimulants 3,052 22,667 25,719 
Cannabinoids 116,690 162,667 279,357 
Hallucinogenic and psychedelic 1,705 52,000 53,705 
Opioid and sedative 6,553 22,667 29,219 
Total 128,000 260,000 388,000 
Estimated number of dependent and casual users 
A dependent user was defined as an individual who used drugs at least weekly and who indicated at 
least one personal harm related to drug use in the past year. Estimated rates of at least one harm 
among frequent users (weekly or more often) were provided in the Health Survey extract. 
Dependent users in each group were calculated by multiplying the estimated number of frequent 
users by the relevant prevalence rate for reported harm. Casual users were estimated as all 
remaining users. 
Drug group Harm 
prevalence 
Dependent Casual Total 
Amphetamine-type stimulants 45.6% 1,392 24,327 25,719 
Cannabinoids 22.3% 26,022 253,335 279,357 
Hallucinogenic and psychedelic 26.4% 450 53,255 53,705 
Opioid and sedative 30.9% 2,025 27,195 29,219 
Total  29,889 358,111 388,000 
Estimated consumption 
Consumption was calculated by multiplying the number of users by the average number of occasions 
of use in a year by the average dose per occasion. User numbers were sourced from the previous 
table. Average number of occasions per year and average doses were derived from Slack et al (2008). 
The allocation of consumption across dependent and casual users was more difficult. There was no 
ready means of estimating this using New Zealand sources. Although not designed for this purpose, 
figures reported by Moore (2007) in an Australian context suggest that the dependent user 
consumes approximately 14 times the amount consumed by a casual user. In our context, this 
translates into daily use by a dependent user compared to an average fortnightly use by a casual 
user. 
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Thus, the proportion allocated to dependents was equivalent to 14 times the number of dependent 
users divided by the total of 14 times the dependent users plus the number of casual users. Details 
are provided below. 
Drug group Amphetamine-
type stimulants 
Cannabinoids Hallucinogenic 
and 
psychedelic 
Opioids 
and 
sedative 
Total users 25,719 279,357 53,705 29,219 
Average occasions 20.4 89.3 7.4 34.2 
Total occasions 524,659 24,946,554 397,420 999,299 
Average dose (g) 0.56 1.10 0.06 0.50 
Total consumption (kg) 294 27,441 24 500 
Dependent consumption (kg) 131 16,186 3 255 
Casual consumption (kg) 163 11,255 21 245 
 
Drug group Amphetamine-
type stimulants 
Cannabinoids Hallucinogenic 
and 
psychedelic 
Opioids 
and 
sedative 
Dependent users 1,392 26,022 450 2,025 
Casual users 24,327 253,335 53,255 27,195 
Moore’s conversion 0.44 0.59 0.11 0.51 
Dependent consumption (kg) 130.66 16,185.78 2.52 255.01 
Casual consumption (kg) 163.15 11,255.43 21.32 244.64 
Average consumption per 
dependent (g) 
93.89 622.01 5.61 125.94 
Average consumption per 
casual (g) 
6.71 44.43 0.40 9.00 
Average consumption per user 
(g) 
11.42 98.23 0.44 17.10 
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Attachment B: Calculation of drug harms 
Sources of data 
Information relating to the prevalence of drug use including consumption was taken from 
Attachment A. 
Other sources included: 
http://www.directfx.co.nz/CurrencyChart.html 
http://www.stats.govt.nz/browse_for_stats/economic_indicators/CPI_inflation/ConsumersPriceInde
x_HOTPJun15qtr.aspx 
Hughes C, Chalmers J, Bright D & McFadden M (2015). Trafficking in multiple commodities: Exposing 
Australia’s polydrug and poly-crime networks. National Drug Law Enforcement Fund, 
Monograph. In press. 
McFadden M (2015). Development of a Proceeds of Crime Disruption Index, New Zealand Police, 
Wellington. 
Melberg H, Hakkarainen P, Houborg E, Jääskeläinen M, Skretting A, Ramstedt M & Rosenqvist P 
(2011). Measuring the harm of illicit drug use on friends and family, Nordic Studies on Alcohol 
and Drugs, 28, 2, 105–121. 
Ministry of Transport (2014). Social Cost of Road Crashes and Injuries 2014 update, Wellington. 
Moore T (2007). Working estimates of the social cost per gram and per user for cannabis, cocaine, 
opiates and amphetamines, Drug Policy Modelling Program Monograph 14, Turning Point. 
Murray C et al (2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 
regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010, The 
Lancet, 380, 2213. 
National Drug Intelligence Bureau (2014). Street-price of drugs. 
Roper T & Thompson A (2006). Estimating the costs of crime in New Zealand in 2003/04, New 
Zealand Treasury Working Paper 06/04. 
United Nations Office on Drugs and Crime (2014). Drug-Related Mortality With Ranking Of Drugs As 
Primary Cause Of Death (2012 Or Latest Year Available), accessed 19 September 2015 at 
www.unodc.org/documents/wdr2014/Statistics/Mortality_2014.xls 
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Personal harm 
Drug-related deaths were taken from the most recent New Zealand submission to the UNODC. There 
were 10 overdose deaths, which were assigned to the opioid and sedatives group. Although not 
mentioned in the submission, a small number of deaths can be attributed to the use of hallucinogens 
and psychedelic drugs. One death per annum was allocated to this group. Cannabis, amphetamines 
and cocaine were ranked in that order as the primary causes of death. As amphetamines and cocaine 
both belong to the same drug group, it was decided to split the remaining deaths between 
amphetamine-type stimulants and cannabinoid groups. The Ministry of Transport 2014 estimate of 
the value of a human life ($3,948,300) was used to calculate the economic cost. 
A top-down approach was adopted to the calculation of harms relating to a reduced quality of life. 
Four studies reported both the harms associated with years of life lost through premature death and 
the years of life lost through disability (Degenhardt et al, 2013; Melberg et al, 2011; Moore, 2007; 
and Murray et al, 2012). There was general agreement between the studies that the overall cost of 
drug-related disability is nearly equivalent to the cost of premature death. Degenhardt et al (2013) is 
the exception, with disability-related costs exceeding those related to premature death by a factor of 
4.58. 
Harms related to disability were estimated to be 103% of those associated with premature death. In 
the absence of other evidence, it was assumed that the multiplier of 103% was the same across drug 
groups. This has the potential to skew results across drug groups. 
Drug group Premature 
deaths 
Estimated cost of: Total harm Dependent 
users 
Cost per 
user premature 
death 
loss of quality 
of life 
Amphetamine-
type stimulants 
32 126,345,600 130,066,581 256,412,181 1,392 184,249 
Cannabinoids 32 126,345,600 130,066,581 256,412,181 26,022 9,854 
Hallucinogenic 
and psychedelic 
1 3,948,300 4,064,581 8,012,881 450 17,797 
Opioid and 
sedative 
10 39,483,000 40,645,806 80,128,806 2,025 39,575 
Total 75 296,122,500 304,843,549 600,966,049 29,889 20,107 
Community harms 
(a) Harm to family and friends 
Melberg et al (2011) conducted research into the harms suffered by family and friends of drug users. 
His report suggested that approximately 50% of the public knew socially, or were related to, a drug 
user (i.e. family and friends). Furthermore, 14% of the family and friends of drug users were willing to 
spend between 500 and 13,000 euros to treat the drug user. Willingness-to-pay is assumed to be 
equivalent to the value of the harm suffered by family and friends. Total harm was distributed across 
drug groups by the number of dependent users. 
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In the absence of any similar data from New Zealand these amounts adjusted to 2014 values were 
applied to the New Zealand population. The amount an individual was willing to pay was set at 500 
euros, the lower end of the range. 
• The 2010 exchange rate of New Zealand dollars to euros was approximately 2. 
• Therefore 500 euros converts to $1,000. 
• The increase in CPI in New Zealand was 5.8% from 2010 to 2014. 
• The current value calculated at $1,058 was rounded to $1,060 for these calculations. 
• The estimated number of family and friends in 2014 was 412,748. 
• Total willingness-to-pay was estimated at $437,512,880. 
Drug type Dependent 
users 
Estimated family 
and friends 
Estimated harm 
($) 
Amphetamine-type stimulants 1,392 19,218.28 20,371,376 
Cannabinoids 26,022 359,351.08 380,912,147 
Hallucinogenic and psychedelic 450 6,217.68 6,590,739 
Opioid and sedative 2,025 27,960.96 29,638,618 
Total 29,889 412,748 437,512,880 
(b) Acquisitive crime 
Acquisitive crime was defined as either (a) unlawful entry with intent / burglary, break and enter, and 
(b) theft and related offences. According to the Statistics New Zealand website there were 53,265 
reported cases of the former and 119,323 of the latter in 2014. Not all cases are reported. Multipliers 
provided by New Zealand Treasury (Roper & Thompson, 2006) were used to estimate unreported 
cases of 63,918 and 564,398 respectively. The average cost of a burglary was $2,704 and theft $603 
based on New Zealand Treasury estimates for 2006 adjusted to 2014 values. There has been 
considerable debate over the proportion of acquisitive crime that could be attributed to drugs. Using 
data from arrestees in 2014 the following table was generated. 
 Methamphetamine Cannabis Ecstasy Opioids Total 
% using in past 12 months 30 68 16 47 161 
% of past-year user reporting 
dependent on drug 
37 32 4 30  
% fulfilling both of the above 11 22 1 14 48 
% adjusted for polydrug use* 7 14 0 9 30 
* The total proportion of arrestees reporting drug use exceeds 100%, indicating significant polydrug use. Final estimates 
were adjusted by 100/161. 
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The above distribution was also used to spread costs over drug groups. Results are provided in the 
following table. 
 Estimate Number of 
dependent 
users 
Cost per 
user ($) 
Number of acquisitive crime 800,904   
Average value of property lost Burglary $2,704 
Theft $603 
  
Total value of property lost $472,476,453   
Total value of drug-related $139,688,690 29,889 4,673 
Amphetamine-type stimulants $32,574,464 1,392 23,401 
Cannabinoids $63,857,687 26,022 2,454 
Hallucinogenic and psychedelic $1,878,167 450 4,174 
Opioid and sedative $41,378,373 2,025 20,434 
(c) Reinvestment in organised crime 
Organised crime reinvests some of its profits into further crime and the remainder into maintaining 
lifestyle. Based on an analysis of New Zealand Police criminal assets data, it is estimated 56% of 
revenue from drug trafficking is reinvested in further criminal activity (McFadden, 2015). Where that 
revenue is invested in drug trafficking, the consequent harm has already been included in the DHI. 
Some of this revenue is invested in other forms of crime, and these have not been included in the 
DHI at this point. A conservative estimate based on Hughes et al (2015) suggests that 20% of criminal 
revenue could be invested in further crime other than drug trafficking. 
The calculation was based on the previously calculated estimate of consumption by drug group and 
user type. These amounts were multiplied by street prices provided by the National Drug Intelligence 
Bureau to generate estimated revenue. Estimated revenue was multiplied by 56% to generate the 
revenue reinvested in crime and the result multiplied by 20% to provide an estimate of the amount 
invested in other crime types. 
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Drug type Amphetamine-
type 
stimulants 
Cannabinoids Hallucinogenic 
and 
psychedelic 
Opioid and 
sedative 
Total 
Dependent 
consumption (kg) 
131 16,186 3 255  
Casual consumption 
(kg) 
163 11,255 21 245  
Price per kg $260,000 $20,000 $75,000 $4,000*  
Income from 
dependent users 
$33,972,331 $323,715,671 $189,275 $1,020,026 $358,897,304 
Income from casual 
users 
$42,417,964 $225,108,519 $1,599,117 $978,572 $270,104,172 
Total income $76,390,296 $548,824,190 $1,788,392 $1,998,597 $629,001,475 
Dependent 
reinvestment 
$3,804,901 $36,256,155 $21,199 $114,243 $40,196,498 
Casual 
reinvestment 
$4,750,812 $25,212,154 $179,101 $109,600 $30,251,667 
Total reinvestment $8,555,713 $61,468,309 $200,300 $223,843 $70,448,165 
Reinvestment per 
dependent user 
$1,247 $311 $12 $17 $314 
Reinvestment per 
casual user 
$210 $155 $3 $5 $116 
Reinvestment per 
user 
$333 $220 $4 $8 $182 
* The majority of these drugs are pharma-opioids and pharma-sedatives. 
(d) Reduced tax base 
The estimate of GST and company tax avoided by organised crime used a similar method to that 
above. Previously calculated estimates of revenue were adjusted by estimated expenses to provide 
estimated profit. McFadden (2015) estimated expenses as 17% of revenue. The GST rate of 15% and 
company tax rate of 32% were applied. It should be noted that GST is normally calculated against 
revenue, not profit. However, it was not possible to estimate GST credits or the impact on revenue of 
adding GST to the sale price of illicit drugs. Basing GST on profit should yield a conservative estimate 
of GST lost. 
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Drug type Amphetamine
-type 
stimulants 
Cannabinoids Hallucinogenic 
and 
psychedelic 
Opioid and 
sedative 
Total 
Income from 
dependent users 
33,972,331 323,715,671 189,275 1,020,026 358,897,304 
Income from casual 
users 
42,417,964 225,108,519 1,599,117 978,572 270,104,172 
Total income 76,390,296 548,824,190 1,788,392 1,998,597 629,001,475 
Profit from dependent 
users 
28,197,035 268,684,007 157,098 846,622 297,884,762 
Profit from casual users 35,206,910 186,840,071 1,327,267 812,215 224,186,463 
Total profit 63,403,946 455,524,078 1,484,365 1,658,836 522,071,224 
GST avoided 
(dependent) 
4,229,555 40,302,601 23,565 126,993 44,682,714 
GST avoided (casual) 5,281,036 28,026,011 199,090 121,832 33,627,969 
Total GST avoided 9,510,592 68,328,6112 222,655 248,825 78,310,684 
Company tax avoided 
(dependent) 
9,023,051 85,978,882 50,271 270,919 95,323,124 
Company tax avoided 
(casual) 
11,266,211 59,788,823 424,725 259,909 71,739,668 
Total company tax 
avoided 
20,289,263 145,767,705 474,997 530,827 167,062,792 
All tax avoided 
(dependent) 
13,252,606 126,281,483 73,836 397,912 140,005,838 
All tax avoided (casual) 16,547,248 87,814,833 623,816 381,741 105,367,638 
Total tax avoided 29,799,854 214,096,317 697,652 779,653 245,373,475 
 
